Survival of patients with multiple myeloma in first-line treatment: thalidomide, dexamethasone and zoledronic acid. Report of the National Cancer Institute of México (INCan)
Espinoza-Zamora, J.R, Labardini-Méndez, J.R, Zapata-Canto, N.P, Aguilar-Rodríguez, M, Vieyra-García, M, Sosa-Espinoza, A, González C, L, Fierro-García, M.G, Nolasco-Medina, D.B, Ríos-Contreras, J.G, Torres-Flores, J.C, Espinoza-Zamora, V.J, Velázquez-Figueroa, J.M, Lozano-Zavaleta, V, Candelaria-Hernández, G.M, Oñate-Ocaña, L.F, Cervera-Ceballos, E.E, Meneses-García, A.A
Published in Clinical lymphoma, myeloma and leukemia (01.09.2015)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2015)
Get full text
Journal Article